IGF-1 DES
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A truncated form of IGF-1 marketed to bodybuilders for tenfold anabolic potency and muscle hyperplasia. The potency edge is real biochemistry, but data is almost entirely animal-based; human evidence is essentially absent, with no safety profile established. The headline risk is severe hypoglycemia (seizures, unconsciousness, death), plus an unresolved concern it could fuel existing tumors. Not FDA-approved; supply is unregulated research-grade product.
Read Full recordStudied uses & evidence
Studied uses(5)
Enhanced anabolic potency (~10x over native IGF-1)
MediumExtensive animal and cell studies show up to 10-fold greater potency; no human trials exist.
Muscle hyperplasia and satellite cell activation
SpeculativeExtrapolated from general IGF-1 muscle biology; no analog-specific or human studies confirm this.
Reduced IGFBP sequestration for greater bioavailability
MediumBinding studies confirm reduced IGFBP affinity; greater bioavailability in humans is inferred, not measured.
Evidence limits
- Evidence Level
- Preclinical only
All direct evidence for Des(1-3)IGF-1 comes from in vitro cell culture studies and in vivo animal models (rodents). No controlled human clinical trials have been conducted on Des(1-3)IGF-1 specifically. The broader IGF-1 system is well-studied in humans, but systemic IGF-1 supplementation in elderly subjects failed to augment muscle strength or protein synthesis (Adams, 2001). Des(1-3)IGF-1 clinical applications have not yet been evaluated in humans.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
AbsoluteIGF-1 DES is 10x more potent than regular IGF-1. Directly promotes tumor cell proliferation.
Diabetic retinopathy
HighPotent IGF-1 activity worsens proliferative retinopathy.
Hypoglycemia-prone individuals
HighPotent glucose-lowering effect. Risk of dangerous hypoglycemia, especially when fasted.
Risk summary(8)
Risks = level of concern: High · Moderate · Low · Theoretical
Severe hypoglycemia — IGF-1 DES has insulin-like glucose-lowering effects that can cause seizures, loss of consciousness, brain damage, and death, particularly when combined with insulin or fasting
HighCancer risk — The IGF-1/IGF1R signaling pathway promotes cell proliferation and survival; elevated IGF-1 is epidemiologically linked to breast, prostate, colorectal, and lung cancers; a potent IGF-1R agonist could accelerate existing tumor growth
ModerateOrgan enlargement (organomegaly) — Animal studies show dose-dependent increases in kidney, heart, liver, lung, and stomach weights (Gillespie et al., 1990)
ModerateSuppression of endogenous GH/IGF-1 axis — Exogenous IGF-1 administration may suppress natural growth hormone secretion via negative feedback
ModerateProduct quality concerns — Research-grade peptides lack pharmaceutical manufacturing controls; products may contain wrong sequences, contaminants, degradation products, or no active peptide
HighNo established human safety profile — All Des(1-3)IGF-1 data is preclinical; adverse effects in humans are unknown and unpredictable
HighInjection site reactions — Localized pain, swelling, or lipohypertrophy at injection sites
LowPotential acromegalic effects — Chronic IGF-1R activation may cause abnormal tissue growth patterns similar to acromegaly
Theoretical
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.